370 related articles for article (PubMed ID: 26183790)
1. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.
Maron BJ; Casey SA; Chan RH; Garberich RF; Rowin EJ; Maron MS
Am J Cardiol; 2015 Sep; 116(5):757-64. PubMed ID: 26183790
[TBL] [Abstract][Full Text] [Related]
2. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
[TBL] [Abstract][Full Text] [Related]
3. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
[TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
5. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
6. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model Among Various Phenotypes in Japanese Patients With Hypertrophic Cardiomyopathy.
Nakagawa S; Okada A; Nishimura K; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Kanzaki H; Kusano K; Yasuda S; Izumi C
Am J Cardiol; 2018 Dec; 122(11):1939-1946. PubMed ID: 30293654
[TBL] [Abstract][Full Text] [Related]
7. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
9. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
[TBL] [Abstract][Full Text] [Related]
10. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
11. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.
Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP
Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643
[TBL] [Abstract][Full Text] [Related]
12. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator.
Maron BJ; Rowin EJ; Maron MS
Heart Rhythm; 2021 Jun; 18(6):1012-1023. PubMed ID: 33508516
[TBL] [Abstract][Full Text] [Related]
13. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy.
Bos JM; Maron BJ; Ackerman MJ; Haas TS; Sorajja P; Nishimura RA; Gersh BJ; Ommen SR
Am J Cardiol; 2010 Nov; 106(10):1481-6. PubMed ID: 21059440
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy.
Leong KMW; Chow JJ; Ng FS; Falaschetti E; Qureshi N; Koa-Wing M; Linton NWF; Whinnett ZI; Lefroy DC; Davies DW; Lim PB; Peters NS; Kanagaratnam P; Varnava AM
Am J Cardiol; 2018 Feb; 121(3):349-355. PubMed ID: 29203036
[TBL] [Abstract][Full Text] [Related]
15. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
[TBL] [Abstract][Full Text] [Related]
16. Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy.
Gatzoulis KA; Georgopoulos S; Antoniou CK; Anastasakis A; Dilaveris P; Arsenos P; Sideris S; Tsiachris D; Archontakis S; Sotiropoulos E; Theopistou A; Skiadas I; Kallikazaros I; Stefanadis C; Tousoulis D
Int J Cardiol; 2018 Mar; 254():175-181. PubMed ID: 29407088
[TBL] [Abstract][Full Text] [Related]
17. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
Maron BJ; Rowin EJ; Casey SA; Link MS; Lesser JR; Chan RH; Garberich RF; Udelson JE; Maron MS
J Am Coll Cardiol; 2015 May; 65(18):1915-28. PubMed ID: 25953744
[TBL] [Abstract][Full Text] [Related]
20. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
Maron BJ; Maron MS
Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]